ArticleBMC cancer2025
Breast cancer incidence in Indonesia: a sex-disaggregated analysis using WHO health equity assessment toolkit data.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Socioeconomic and health system determinants of maternal health inequities across Chinese provinces (2009-2021): a multivariate meta-regression analysis of regional heterogeneity in underlying mechanisms.Frontiers in public health · 2026Pooled it
- Image quality comparison of synthesized two-dimensional images and digital mammography in breast tomosynthesis: A quantitative analysis.Journal of applied clinical medical physics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBreast cancer is the most common cancer among women globally, with notable disparities in incidence between sexes, particularly in low and middle-income countries. Understanding these disparities is essential for tackling health inequities, particularly in Indonesia, where access to screening and treatment is spatially inconsistent. This study examined the trends and disparities in breast cancer incidence in Indonesia from 2000 to 2019, utilizing sex-disaggregated data from the World Health Organization's Health Equity Assessment Toolkit (HEAT).
methodsAge-standardized breast cancer incidence rates (per 100,000 population) from the WHO HEAT were measured. The HEAT platform sources data from the Institute for Health Metrics and Evaluation (IHME), which compiles data from national cancer registries and health surveys. Four inequality indicators were calculated to assess the absolute and relative differences in breast cancer incidence between males and females: Difference, Ratio, Population Attributable Fraction, and Population Attributable Risk. All estimates were presented with Confidence Intervals (CI).
resultsBetween 2000 and 2019, the age-standardized incidence of breast cancer in Indonesia declined from 19.1 to 16.0 per 100,000 population. Nonetheless, considerable sex disparities remained. In 2019, the incidence rate for females was 37.4 (CI: 29.0-48.6), whereas for males it was 0.4 (CI: 0.2-0.5). The absolute difference in incidence between sexes rose from 31.0 in 2000 to 37.1 in 2019. The relative disparity persisted, with females being over 100 times more predisposed to breast cancer than males (ratio = 104.4 in 2019). The population attributable fraction and population attributable risk values continuously demonstrated that almost all breast cancer cases were associated with females. PAF values fluctuated from - 98.6% in 2000 to -98.1% in 2019.
conclusionsThe incidence of breast cancer in Indonesia is declining; yet, sex disparities remain, with females bearing a disproportionately greater burden. These findings underscore the need for targeted public health strategies, including expanded access to breast cancer screening programs, public awareness campaigns to promote early detection, and improved availability of diagnostic and treatment services tailored to women. Future research ought to identify and mitigate female-specific risk factors, such as hormonal and reproductive factors, and lifestyle impacts, to enhance prevention measures, are critical for reducing these disparities and improving health outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.